TrialBone marrow transplantation2019

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.

Jun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.